Duchenne muscular dystrophy

被引:2
|
作者
Susan T. Iannaccone
Zohair Nanjiani
机构
[1] The University of Texas Southwestern Medical Center,Department of Neuromuscular Disease and Neurorehabilitation
[2] Texas Scottish Rite Hospital for Children,undefined
关键词
Muscular Dystrophy; Duchenne Muscular Dystrophy; Duchenne Muscular Dystrophy; Pulmonary Rehabilitation; Muscle Nerve;
D O I
10.1007/s11940-001-0045-2
中图分类号
学科分类号
摘要
Duchenne muscular dystrophy (DMD) is not treatable; there is no cure. More than a decade ago, randomized trials demonstrated that oral steroid therapy was of benefit to DMD patients by prolonging ambulation. Although few significant side effects were reported, study patients were followed for 18 months or less. However, when treating DMD with steroids, the clinician must consider beginning treatment in mid-childhood and continuing until adolescence or longer, a total of at least 10 years. There is no evidence that steroids are associated with prolonged life or with improved pulmonary or cardiac function in DMD. It is clear that the risk of side effects increases with duration of use of oral steroids. Therefore, oral steroids are not recommended for treatment of DMD on a routine basis. If, in certain cases, one does institute therapy, the patient should be monitored carefully for side effects, maintain dietary restriction, and exercise regularly.
引用
收藏
页码:105 / 117
页数:12
相关论文
共 50 条
  • [31] Adults with Duchenne Muscular Dystrophy
    Eagle, Michelle
    Straub, Volker
    Bushby, Kate
    NEUROMUSCULAR DISORDERS, 2006, 16 : S120 - S120
  • [32] Challenges in Duchenne muscular dystrophy
    Davies, KE
    NEUROMUSCULAR DISORDERS, 1997, 7 (08) : 482 - 486
  • [33] Biomarkers in Duchenne Muscular Dystrophy
    Theo Lee-Gannon
    Xuan Jiang
    Tara C. Tassin
    Pradeep P. A. Mammen
    Current Heart Failure Reports, 2022, 19 : 52 - 62
  • [34] DUCHENNE MUSCULAR-DYSTROPHY
    SUGITA, H
    JAPANESE JOURNAL OF HUMAN GENETICS, 1987, 32 (02): : 119 - 121
  • [35] Electrocardiogram in Duchenne muscular dystrophy
    Velayutham, R.
    Anitha, R. M.
    Vellingiri, Sureshkumar
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2024,
  • [36] Golodirsen for Duchenne muscular dystrophy
    Anwar, S.
    Yokota, T.
    DRUGS OF TODAY, 2020, 56 (08) : 491 - 504
  • [37] Update on Duchenne muscular dystrophy
    Leiva-Cepas, F.
    Montano Martinez, A.
    Lopez-Lopez, I
    MEDICINA DE FAMILIA-SEMERGEN, 2021, 47 (07): : 472 - 481
  • [38] Duchenne muscular dystrophy and epilepsy
    Pane, M.
    Messina, S.
    Bruno, C.
    D'Amico, A.
    Villanova, M.
    Brancalion, B.
    Sivo, S.
    Bianco, F.
    Striano, P.
    Battaglia, D.
    Letiori, D.
    Vita, G. L.
    Bertini, E.
    Gualandi, F.
    Ricotti, V.
    Ferlini, A.
    Mercuri, E.
    NEUROMUSCULAR DISORDERS, 2013, 23 (04) : 313 - 315
  • [39] Duchenne muscular dystrophy - Reply
    Simonds, AK
    THORAX, 1999, 54 (06) : 564 - 564
  • [40] Casimersen for Duchenne muscular dystrophy
    Wilton-Clark, H.
    Yokota, T.
    DRUGS OF TODAY, 2021, 57 (12) : 707 - 717